Rewrite without altering any single word of following questions - 1. A

Rewrite without altering any single word of following questions - ## 1. Antitussives and Expectorants These agents manage respiratory conditions by either suppressing the cough reflex or facilitating mucus clearance. ## Classification and Mechanisms * Central Antitussives (Opioids): Codeine, dextromethorphan. They suppress the cough center in the medulla oblongata. * Peripheral Antitussives: Prenoxdiazine, levodropropizine. They reduce the sensitivity of respiratory tract stretch receptors. * Secretomotor Expectorants: Ammonium chloride, potassium iodide. They irritate the gastric mucosa to reflexively increase bronchial secretions. * Mucolytics: N-acetylcysteine, ambroxol, bromhexine. N-acetylcysteine breaks disulfide bonds in mucoproteins to liquefy mucus. Ambroxol stimulates surfactant production. ## Indications * Antitussives: Dry, non-productive, exhausting coughs (e.g., post-viral cough, lung cancer). * Expectorants/Mucolytics: Productive coughs with thick, viscous sputum (e.g., bronchitis, COPD, cystic fibrosis). ## Side Effects * Opioid Antitussives: Sedation, constipation, respiratory depression, addiction potential. * Expectorants/Mucolytics: Gastrointestinal irritation, nausea, bronchospasm (especially with inhaled mucolytics in asthmatics). ------------------------------ ## 2. Bronchodilators Bronchodilators relax bronchial smooth muscle to reverse airway obstruction. ## Classification and Mechanisms * β₂-Adrenergic Agonists: * SABA (Short-Acting): Salbutamol, albuterol. * LABA (Long-Acting): Salmeterol, formoterol. * Mechanism: Stimulate β₂-receptors → activate adenylyl cyclase → increase cAMP → smooth muscle relaxation. * Anticholinergics (Muscarinic Antagonists): * SAMA: Ipratropium bromide. * LAMA: Tiotropium bromide. * Mechanism: Block M₃ muscarinic receptors → inhibit vagal bronchoconstriction and mucus secretion. * Methylxanthines: Theophylline, aminophylline. * Mechanism: Inhibit phosphodiesterase (PDE), increasing cAMP. They also block adenosine receptors. ## Treatment of Asthma and Broncho-Obstructive Syndromes * Acute Asthma Exacerbation: Fast-acting SABAs (salbutamol) serve as first-line rescue therapy, often combined with SAMAs (ipratropium). * Chronic Asthma Maintenance: Formoterol or salmeterol are used, always paired with an inhaled corticosteroid (ICS) to manage inflammation. * COPD Management: LAMAs and LABAs are the foundational maintenance therapies to minimize air trapping. ## Side Effects * β₂-Agonists: Skeletal muscle tremors, tachycardia, palpitations, hypokalemia. * Anticholinergics: Dry mouth, urinary retention, blurred vision, constipation. * Methylxanthines: Narrow therapeutic window. Causes insomnia, severe arrhythmias, seizures, and vomiting. ------------------------------ ## 3. Cardiac Glycosides Cardiac glycosides (e.g., Digoxin) are positive inotropic and negative chronotropic agents derived from Digitalis plants. ## Mechanisms of Action * Inhibition of Na⁺/K⁺-ATPase Pump: Digoxin binds to this membrane pump, increasing intracellular Na⁺. This slows the Na⁺/Ca²⁺-exchanger, raising intracellular Ca²⁺ accumulation in the sarcoplasmic reticulum, which enhances cardiac contractility (Positive Inotropy). * Heart Rate and Conduction: Increases vagal (parasympathetic) tone. This slows the sinoatrial (SA) node firing rate (Negative Chronotropy) and prolongs conduction through the atrioventricular (AV) node (Negative Dromotropy). * Hemodynamics: Increases cardiac output in failing hearts, lowers left ventricular end-diastolic pressure, and reduces systemic vascular resistance via baroreceptor restoration. * Renal Function: Increased cardiac output improves renal perfusion. This promotes diuresis and reduces renin-angiotensin-aldosterone system (RAAS) activation. ## Indications * Chronic heart failure with reduced ejection fraction (HFrEF) symptomatic despite optimal therapy. * Ventricular rate control in patients with atrial fibrillation or atrial flutter. ------------------------------ ## 4. Glycoside Intoxication (Digitalis Toxicity) Digoxin has a very narrow therapeutic index (0.5 - 2.0 ng/mL), making toxicity a frequent clinical challenge. ## Pathogenesis and Contributing Factors Toxicity is driven by excessive intracellular Ca²⁺ overload and severe Na⁺/K⁺-ATPase inhibition. Hypokalemia worsens toxicity because potassium competes with digoxin for the pump binding site. Hypomagnesemia and hypercalcemia also increase sensitivity. ## Stages and Symptoms * Gastrointestinal (Early): Anorexia, nausea, vomiting, abdominal pain. * Neurological/Visual: Fatigue, confusion, delirium, xanthopsia (yellow-green halos around lights). * Cardiac (Late/Severe): Increased automaticity combined with decreased AV conduction. Leads to premature ventricular contractions (PVCs), bidirectional ventricular tachycardia, or high-degree AV blocks. ## Management 1. Discontinuation: Stop digoxin and any potassium-wasting diuretics immediately. 2. Electrolyte Correction: Administer potassium if hypokalemia is present (maintain normal-to-high levels, provided there is no high-degree AV block). 3. Antiarrhythmics: Phenytoin or lidocaine are preferred for digitalis-induced ventricular arrhythmias. Avoid Class IA agents and calcium channel blockers. 4. Specific Antidote: Administer Digoxin-specific antibody fragments (DigiFab) for life-threatening arrhythmias, severe hyperkalemia, or massive overdoses. [1] ------------------------------ ## 5. Antiarrhythmic Agents Class I Class I antiarrhythmics block voltage-gated sodium channels (Na⁺ channels) during Phase 0 of the cardiac action potential. ## Classification and Mechanisms * Class IA (Moderate block; prolongs repolarization): Quinidine, procainamide, disopyramide. They block Na⁺ channels and block K⁺ channels, prolonging the action potential duration (APD) and QT interval. * Class IB (Weak block; shortens repolarization): Lidocaine, mexiletine. They bind preferentially to inactivated Na⁺ channels in ischemic tissues, shortening APD. * Class IC (Strong block; no effect on repolarization): Flecainide, propafenone. They markedly slow Phase 0 depolarization and significantly decrease conduction velocity with minimal effect on APD. Phase 0 Depolarization Slope: Normal Action Potential: / Class IB Alteration: / (Mild decrease) Class IA Alteration: / (Moderate decrease) Class IC Alteration: / (Severe flattening) ## Indications * Class IA: Atrial fibrillation rhythm control, ventricular tachycardia. * Class IB: Acute ventricular arrhythmias, particularly post-myocardial infarction or digitalis-induced. * Class IC: Supraventricular tachycardias (SVT), atrial fibrillation in patients without structural heart disease. ## Side Effects * Class IA: Torsades de pointes (due to prolonged QT), drug-induced lupus (procainamide), cinchonism (quinidine). * Class IB: CNS toxicity (confusion, paresthesias, seizures, slurred speech). * Class IC: Highly proarrhythmic (especially post-MI, as demonstrated in the CAST trial), metallic taste (propafenone). ------------------------------ ## 6. Calcium Channel Blockers (CCBs) CCBs inhibit the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac cells. ## Classification and Mechanisms * Dihydropyridines (Vascular-selective): Amlodipine, nifedipine, felodipine. * Mechanism: Bind to vascular smooth muscle L-type channels → cause marked peripheral vasodilation with minimal direct cardiac effects. * Non-Dihydropyridines (Cardio-selective): Verapamil (phenylalkylamine), diltiazem (benzothiazepine). * Mechanism: Bind to L-type channels in the myocardium, SA node, and AV node → decrease contractility (negative inotropy), heart rate (negative chronotropy), and conduction velocity (negative dromotropy). ## Indications * Dihydropyridines: Hypertension, angina pectoris, Raynaud's phenomenon. * Non-Dihydropyridines: Rate control in atrial fibrillation/flutter, supraventricular tachycardia (SVT) prophylaxis, angina pectoris. ## Side Effects * Dihydropyridines: Peripheral edema, reflex tachycardia, flushing, headaches. * Non-Dihydropyridines: Bradycardia, AV block, constipation (especially verapamil), exacerbation of HFrEF. ------------------------------ ## 7. Nitrates Nitrates are prodrugs that act as potent vasodilators, primarily affecting the venous system. ## Mechanisms and Features of Action * Biotransformation: Nitrates (e.g., nitroglycerin, isosorbide dinitrate) are denitrated to release Nitric Oxide (NO). * Intracellular Pathway: NO stimulates soluble guanylyl cyclase → increases intracellular cyclic GMP (cGMP) → activates protein kinase G → dephosphorylation of myosin light chains → smooth muscle relaxation. * Hemodynamic Effects: At therapeutic doses, nitrates cause venous dilation over arterial dilation. This increases venous capacitance, reduces venous return (preload), and lowers left ventricular wall tension, which decreases myocardial oxygen demand. Higher doses cause arterial dilation, reducing afterload. * Nitrate Tolerance: Continuous exposure leads to a depletion of sulfhydryl groups or increased free radical production, neutralizing the drug's effect. A nitrate-free interval of 10-12 hours daily is mandatory to prevent this. ## Use * Acute relief and prophylaxis of angina pectoris. * Acute decompensated heart failure (to rapidly reduce preload). * Hypertensive emergencies (intravenous nitroglycerin). ## Side Effects * Throbbing headache (due to meningeal artery dilation). * Reflex tachycardia (due to baroreceptor response to blood pressure drops). * Orthostatic hypotension, dizziness, facial flushing. * Contraindication: Absolute contraindication with phosphodiesterase-5 (PDE-5) inhibitors like sildenafil, which can lead to life-threatening hypotension. ------------------------------ ## 8. Lipid-Lowering Agents Lipid-lowering agents alter plasma lipoprotein metabolism to decrease atherosclerotic plaque formation. ## Classification and Principles of Action * HMG-CoA Reductase Inhibitors (Statins): Inhibit cholesterol synthesis. * Cholesterol Absorption Inhibitors: Ezetimibe. Blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the intestine to lower dietary cholesterol uptake. * PCSK9 Inhibitors: Alirocumab, evolocumab. Monoclonal antibodies that prevent LDL receptor degradation, leaving more receptors available to clear LDL from the blood. * Fibric Acid Derivatives (Fibrates): Fenofibrate, gemfibrozil. Activate PPAR-alpha to upregulate lipoprotein lipase, primarily clearing triglycerides. * Bile Acid Sequestrants: Cholestyramine, colesevelam. Bind bile acids in the gut, forcing the liver to consume plasma cholesterol to synthesize new bile. ## Statins: Mechanism, Indications, and Side Effects * Mechanism: Competitively inhibit HMG-CoA reductase. This halts the conversion of HMG-CoA to mevalonate (the rate-limiting step in cholesterol synthesis). Decreased intracellular cholesterol triggers the liver to upregulate surface LDL receptors, removing circulating LDL from the blood. * Indications: Hypercholesterolemia, primary and secondary prevention of cardiovascular events (e.g., myocardial infarction, stroke). [1] * Side Effects: Myalgia, myopathy, rare rhabdomyolysis (risk increases when combined with fibrates or CYP3A4 inhibitors), elevated liver transaminases (hepatotoxicity), and a slight increase in blood glucose levels. Statins are strictly contraindicated in pregnancy. ------------------------------ ## 9. Diuretics: Classification and General Mechanisms Diuretics increase urine volume by altering the transport of sodium and water across the nephron, thereby lowering blood volume and pressure. [2] [NEPHRON SITE MAP] Cortex (PCT) --> (DCT) ---------+ | | v v Medulla (Loop of Henle) -----> (Collecting Duct) ## Classification by Site of Nephron Action 1. Proximal Convoluted Tubule (PCT): Carbonic anhydrase inhibitors, Osmotic diuretics. 2. Thick Ascending Limb of the Loop of Henle: Loop diuretics. 3. Distal Convoluted Tubule (DCT): Thiazide and thiazide-like diuretics. 4. Cortical Collecting Tubule: Potassium-sparing diuretics. ------------------------------ ## 10. Carbonic Anhydrase Inhibitors and Osmotic Diuretics These agents work early in the nephron but are rarely used for systemic edema due to weak diuretic efficacy. ## Carbonic Anhydrase Inhibitors (e.g., Acetazolamide) * Mechanism: Inhibits carbonic anhydrase in the PCT lumen and cytoplasm. This halts the conversion of H₂CO₃ into CO₂ and H₂O, preventing NaHCO₃ reabsorption and forcing sodium and bicarbonate to remain in the urine. * Features: Causes significant alkaline diuresis and metabolic acidosis. * Uses: Glaucoma (reduces aqueous humor production), acute mountain sickness, urinary alkalinization. * Side Effects: Hyperchloremic metabolic acidosis, hypokalemia, kidney stones (calcium phosphate precipitates in alkaline urine), sulfonamide allergy hypersensitivity. [3] ## Osmotic Diuretics (e.g., Mannitol) [4] * Mechanism: Mannitol is a non-absorbable solute filtered freely at the glomerulus. It acts along the entire tubule (mainly the PCT and descending loop) to create an osmotic gradient that holds water in the lumen. * Features: It extracts water from intracellular compartments into the bloodstream before it is filtered, expanding extracellular fluid volume initially. * Uses: Reduction of intracranial pressure (cerebral edema), reduction of intraocular pressure. * Side Effects: Transient extracellular volume expansion (can precipitate acute pulmonary edema or heart failure), dehydration, hypernatremia. ------------------------------ ## 11. Loop Diuretics, Thiazides, and Thiazide-Like Diuretics These are the primary drug classes used to manage volume overload and hypertension. ## Loop Diuretics (e.g., Furosemide, Bumetanide, Torsemide) * Mechanism: Reversibly inhibit the Na⁺/K⁺/2Cl⁻ cotransporter (NKCC2) in the thick ascending limb of the loop of Henle. By blocking this transporter, they halt the reabsorption of 25% of the filtered sodium load. They also disrupt the lumen-positive potential, preventing Ca²⁺ and Mg²⁺ reabsorption. * Features: High-ceiling diuretics with potent action. They remain effective even in patients with low glomerular filtration rates (GFR). * Indications: Acute pulmonary edema, chronic heart failure edema, hepatic cirrhosis edema, renal failure edema, severe hypercalcemia. * Side Effects: Hypokalemia, metabolic alkalosis, hypomagnesemia, hypocalcemia, hyperuricemia (gout flare), ototoxicity (hearing loss), sulfonamide allergy. ## Thiazide and Thiazide-Like Diuretics (e.g., Hydrochlorothiazide, Chlorthalidone, Indapamide) * Mechanism: Inhibit the Na⁺/Cl⁻ cotransporter (NCC) in the early distal convoluted tubule, blocking 5-10% of sodium reabsorption. This increases distal delivery of sodium, which enhances Ca²⁺ reabsorption in the DCT via the basolateral Na⁺/Ca²⁺ exchanger. * Features: They lose efficacy when GFR drops below 30 mL/min (except indapamide and metolazone). * Indications: Essential hypertension (first-line), mild heart failure edema, nephrogenic diabetes insipidus, calcium nephrolithiasis (hypercalciuria prevention). * Side Effects: Hypokalemia, metabolic alkalosis, hyponatremia, hypercalcemia, hyperuricemia, hyperglycemia, hyperlipidemia.

Here is the rewritten version with identical wording, reformatted for clarity:

1. Antitussives and Expectorants

These agents manage respiratory conditions by either suppressing the cough reflex or facilitating mucus clearance.

Classification and Mechanisms

Central Antitussives (Opioids): Codeine, dextromethorphan. They suppress the cough center in the medulla oblongata.

Peripheral Antitussives: Prenoxdiazine, levodropropizine. They reduce the sensitivity of respiratory tract stretch receptors.

Secretomotor Expectorants: Ammonium chloride, potassium iodide. They irritate the gastric mucosa to reflexively increase bronchial secretions.

Mucolytics: N-acetylcysteine, ambroxol, bromhexine. N-acetylcysteine breaks disulfide bonds in mucoproteins to liquefy mucus. Ambroxol stimulates surfactant production.

Indications

Antitussives: Dry, non-productive, exhausting coughs (e.g., post-viral cough, lung cancer).

Expectorants/Mucolytics: Productive coughs with thick, viscous sputum (e.g., bronchitis, COPD, cystic fibrosis).

Side Effects

Opioid Antitussives: Sedation, constipation, respiratory depression, addiction potential.

Expectorants/Mucolytics: Gastrointestinal irritation, nausea, bronchospasm (especially with inhaled mucolytics in asthmatics).

2. Bronchodilators

Bronchodilators relax bronchial smooth muscle to reverse airway obstruction.

Classification and Mechanisms

β₂-Adrenergic Agonists:

SABA (Short-Acting): Salbutamol, albuterol.
LABA (Long-Acting): Salmeterol, formoterol.
Mechanism: Stimulate β₂-receptors → activate adenylyl cyclase → increase cAMP → smooth muscle relaxation.

Anticholinergics (Muscarinic Antagonists):

SAMA: Ipratropium bromide.
LAMA: Tiotropium bromide.
Mechanism: Block M₃ muscarinic receptors → inhibit vagal bronchoconstriction and mucus secretion.

Methylxanthines: Theophylline, aminophylline.

Mechanism: Inhibit phosphodiesterase (PDE), increasing cAMP. They also block adenosine receptors.

Treatment of Asthma and Broncho-Obstructive Syndromes

Acute Asthma Exacerbation: Fast-acting SABAs (salbutamol) serve as first-line rescue therapy, often combined with SAMAs (ipratropium).

Chronic Asthma Maintenance: Formoterol or salmeterol are used, always paired with an inhaled corticosteroid (ICS) to manage inflammation.

COPD Management: LAMAs and LABAs are the foundational maintenance therapies to minimize air trapping.

Side Effects

β₂-Agonists: Skeletal muscle tremors, tachycardia, palpitations, hypokalemia.

Anticholinergics: Dry mouth, urinary retention, blurred vision, constipation.

Methylxanthines: Narrow therapeutic window. Causes insomnia, severe arrhythmias, seizures, and vomiting.

3. Cardiac Glycosides

Cardiac glycosides (e.g., Digoxin) are positive inotropic and negative chronotropic agents derived from Digitalis plants.

Mechanisms of Action

Inhibition of Na⁺/K⁺-ATPase Pump: Digoxin binds to this membrane pump, increasing intracellular Na⁺. This slows the Na⁺/Ca²⁺-exchanger, raising intracellular Ca²⁺ accumulation in the sarcoplasmic reticulum, which enhances cardiac contractility (Positive Inotropy).

Heart Rate and Conduction: Increases vagal (parasympathetic) tone. This slows the sinoatrial (SA) node firing rate (Negative Chronotropy) and prolongs conduction through the atrioventricular (AV) node (Negative Dromotropy).

Hemodynamics: Increases cardiac output in failing hearts, lowers left ventricular end-diastolic pressure, and reduces systemic vascular resistance via baroreceptor restoration.

Renal Function: Increased cardiac output improves renal perfusion. This promotes diuresis and reduces renin-angiotensin-aldosterone system (RAAS) activation.

Indications

Chronic heart failure with reduced ejection fraction (HFrEF) symptomatic despite optimal therapy.
Ventricular rate control in patients with atrial fibrillation or atrial flutter.

4. Glycoside Intoxication (Digitalis Toxicity)

Digoxin has a very narrow therapeutic index (0.5 - 2.0 ng/mL), making toxicity a frequent clinical challenge.

Pathogenesis and Contributing Factors

Toxicity is driven by excessive intracellular Ca²⁺ overload and severe Na⁺/K⁺-ATPase inhibition. Hypokalemia worsens toxicity because potassium competes with digoxin for the pump binding site. Hypomagnesemia and hypercalcemia also increase sensitivity.

Stages and Symptoms

Gastrointestinal (Early): Anorexia, nausea, vomiting, abdominal pain.

Neurological/Visual: Fatigue, confusion, delirium, xanthopsia (yellow-green halos around lights).

Cardiac (Late/Severe): Increased automaticity combined with decreased AV conduction. Leads to premature ventricular contractions (PVCs), bidirectional ventricular tachycardia, or high-degree AV blocks.

Management

Discontinuation: Stop digoxin and any potassium-wasting diuretics immediately.
Electrolyte Correction: Administer potassium if hypokalemia is present (maintain normal-to-high levels, provided there is no high-degree AV block).
Antiarrhythmics: Phenytoin or lidocaine are preferred for digitalis-induced ventricular arrhythmias. Avoid Class IA agents and calcium channel blockers.
Specific Antidote: Administer Digoxin-specific antibody fragments (DigiFab) for life-threatening arrhythmias, severe hyperkalemia, or massive overdoses. [1]

5. Antiarrhythmic Agents - Class I

Class I antiarrhythmics block voltage-gated sodium channels (Na⁺ channels) during Phase 0 of the cardiac action potential.

Classification and Mechanisms

Class IA (Moderate block; prolongs repolarization): Quinidine, procainamide, disopyramide. They block Na⁺ channels and block K⁺ channels, prolonging the action potential duration (APD) and QT interval.

Class IB (Weak block; shortens repolarization): Lidocaine, mexiletine. They bind preferentially to inactivated Na⁺ channels in ischemic tissues, shortening APD.

Class IC (Strong block; no effect on repolarization): Flecainide, propafenone. They markedly slow Phase 0 depolarization and significantly decrease conduction velocity with minimal effect on APD.

Action Potential	Phase 0 Depolarization Slope
Normal	/
Class IB Alteration	/ (Mild decrease)
Class IA Alteration	/ (Moderate decrease)
Class IC Alteration	/ (Severe flattening)

Indications

Class IA: Atrial fibrillation rhythm control, ventricular tachycardia.

Class IB: Acute ventricular arrhythmias, particularly post-myocardial infarction or digitalis-induced.

Class IC: Supraventricular tachycardias (SVT), atrial fibrillation in patients without structural heart disease.

Side Effects

Class IA: Torsades de pointes (due to prolonged QT), drug-induced lupus (procainamide), cinchonism (quinidine).

Class IB: CNS toxicity (confusion, paresthesias, seizures, slurred speech).

Class IC: Highly proarrhythmic (especially post-MI, as demonstrated in the CAST trial), metallic taste (propafenone).

6. Calcium Channel Blockers (CCBs)

CCBs inhibit the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac cells.

Classification and Mechanisms

Dihydropyridines (Vascular-selective): Amlodipine, nifedipine, felodipine.

Mechanism: Bind to vascular smooth muscle L-type channels → cause marked peripheral vasodilation with minimal direct cardiac effects.

Non-Dihydropyridines (Cardio-selective): Verapamil (phenylalkylamine), diltiazem (benzothiazepine).

Mechanism: Bind to L-type channels in the myocardium, SA node, and AV node → decrease contractility (negative inotropy), heart rate (negative chronotropy), and conduction velocity (negative dromotropy).

Indications

Dihydropyridines: Hypertension, angina pectoris, Raynaud's phenomenon.

Non-Dihydropyridines: Rate control in atrial fibrillation/flutter, supraventricular tachycardia (SVT) prophylaxis, angina pectoris.

Side Effects

Dihydropyridines: Peripheral edema, reflex tachycardia, flushing, headaches.

Non-Dihydropyridines: Bradycardia, AV block, constipation (especially verapamil), exacerbation of HFrEF.

7. Nitrates

Nitrates are prodrugs that act as potent vasodilators, primarily affecting the venous system.

Mechanisms and Features of Action

Biotransformation: Nitrates (e.g., nitroglycerin, isosorbide dinitrate) are denitrated to release Nitric Oxide (NO).

Intracellular Pathway: NO stimulates soluble guanylyl cyclase → increases intracellular cyclic GMP (cGMP) → activates protein kinase G → dephosphorylation of myosin light chains → smooth muscle relaxation.

Hemodynamic Effects: At therapeutic doses, nitrates cause venous dilation over arterial dilation. This increases venous capacitance, reduces venous return (preload), and lowers left ventricular wall tension, which decreases myocardial oxygen demand. Higher doses cause arterial dilation, reducing afterload.

Nitrate Tolerance: Continuous exposure leads to a depletion of sulfhydryl groups or increased free radical production, neutralizing the drug's effect. A nitrate-free interval of 10-12 hours daily is mandatory to prevent this.

Use

Acute relief and prophylaxis of angina pectoris.
Acute decompensated heart failure (to rapidly reduce preload).
Hypertensive emergencies (intravenous nitroglycerin).

Side Effects

Throbbing headache (due to meningeal artery dilation).
Reflex tachycardia (due to baroreceptor response to blood pressure drops).
Orthostatic hypotension, dizziness, facial flushing.
Contraindication: Absolute contraindication with phosphodiesterase-5 (PDE-5) inhibitors like sildenafil, which can lead to life-threatening hypotension.

8. Lipid-Lowering Agents

Lipid-lowering agents alter plasma lipoprotein metabolism to decrease atherosclerotic plaque formation.

Classification and Principles of Action

HMG-CoA Reductase Inhibitors (Statins): Inhibit cholesterol synthesis.

Cholesterol Absorption Inhibitors: Ezetimibe. Blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the intestine to lower dietary cholesterol uptake.

PCSK9 Inhibitors: Alirocumab, evolocumab. Monoclonal antibodies that prevent LDL receptor degradation, leaving more receptors available to clear LDL from the blood.

Fibric Acid Derivatives (Fibrates): Fenofibrate, gemfibrozil. Activate PPAR-alpha to upregulate lipoprotein lipase, primarily clearing triglycerides.

Bile Acid Sequestrants: Cholestyramine, colesevelam. Bind bile acids in the gut, forcing the liver to consume plasma cholesterol to synthesize new bile.

Statins: Mechanism, Indications, and Side Effects

Mechanism: Competitively inhibit HMG-CoA reductase. This halts the conversion of HMG-CoA to mevalonate (the rate-limiting step in cholesterol synthesis). Decreased intracellular cholesterol triggers the liver to upregulate surface LDL receptors, removing circulating LDL from the blood.

Indications: Hypercholesterolemia, primary and secondary prevention of cardiovascular events (e.g., myocardial infarction, stroke). [1]

Side Effects: Myalgia, myopathy, rare rhabdomyolysis (risk increases when combined with fibrates or CYP3A4 inhibitors), elevated liver transaminases (hepatotoxicity), and a slight increase in blood glucose levels. Statins are strictly contraindicated in pregnancy.

9. Diuretics: Classification and General Mechanisms

Diuretics increase urine volume by altering the transport of sodium and water across the nephron, thereby lowering blood volume and pressure. [2]

[NEPHRON SITE MAP]
Cortex  (PCT) --> (DCT) ---------+
                                 |
                                 |
                                 v                    v
Medulla (Loop of Henle) -----> (Collecting Duct)

Classification by Site of Nephron Action

Proximal Convoluted Tubule (PCT): Carbonic anhydrase inhibitors, Osmotic diuretics.
Thick Ascending Limb of the Loop of Henle: Loop diuretics.
Distal Convoluted Tubule (DCT): Thiazide and thiazide-like diuretics.
Cortical Collecting Tubule: Potassium-sparing diuretics.

10. Carbonic Anhydrase Inhibitors and Osmotic Diuretics

These agents work early in the nephron but are rarely used for systemic edema due to weak diuretic efficacy.

Carbonic Anhydrase Inhibitors (e.g., Acetazolamide)

Mechanism: Inhibits carbonic anhydrase in the PCT lumen and cytoplasm. This halts the conversion of H₂CO₃ into CO₂ and H₂O, preventing NaHCO₃ reabsorption and forcing sodium and bicarbonate to remain in the urine.

Features: Causes significant alkaline diuresis and metabolic acidosis.

Uses: Glaucoma (reduces aqueous humor production), acute mountain sickness, urinary alkalinization.

Side Effects: Hyperchloremic metabolic acidosis, hypokalemia, kidney stones (calcium phosphate precipitates in alkaline urine), sulfonamide allergy hypersensitivity. [3]

Osmotic Diuretics (e.g., Mannitol) [4]

Mechanism: Mannitol is a non-absorbable solute filtered freely at the glomerulus. It acts along the entire tubule (mainly the PCT and descending loop) to create an osmotic gradient that holds water in the lumen.

Features: It extracts water from intracellular compartments into the bloodstream before it is filtered, expanding extracellular fluid volume initially.

Uses: Reduction of intracranial pressure (cerebral edema), reduction of intraocular pressure.

Side Effects: Transient extracellular volume expansion (can precipitate acute pulmonary edema or heart failure), dehydration, hypernatremia.

11. Loop Diuretics, Thiazides, and Thiazide-Like Diuretics

These are the primary drug classes used to manage volume overload and hypertension.

Loop Diuretics (e.g., Furosemide, Bumetanide, Torsemide)

Mechanism: Reversibly inhibit the Na⁺/K⁺/2Cl⁻ cotransporter (NKCC2) in the thick ascending limb of the loop of Henle. By blocking this transporter, they halt the reabsorption of 25% of the filtered sodium load. They also disrupt the lumen-positive potential, preventing Ca²⁺ and Mg²⁺ reabsorption.

Features: High-ceiling diuretics with potent action. They remain effective even in patients with low glomerular filtration rates (GFR).

Indications: Acute pulmonary edema, chronic heart failure edema, hepatic cirrhosis edema, renal failure edema, severe hypercalcemia.

Side Effects: Hypokalemia, metabolic alkalosis, hypomagnesemia, hypocalcemia, hyperuricemia (gout flare), ototoxicity (hearing loss), sulfonamide allergy.

Thiazide and Thiazide-Like Diuretics (e.g., Hydrochlorothiazide, Chlorthalidone, Indapamide)

Mechanism: Inhibit the Na⁺/Cl⁻ cotransporter (NCC) in the early distal convoluted tubule, blocking 5-10% of sodium reabsorption. This increases distal delivery of sodium, which enhances Ca²⁺ reabsorption in the DCT via the basolateral Na⁺/Ca²⁺ exchanger.

Features: They lose efficacy when GFR drops below 30 mL/min (except indapamide and metolazone).

Indications: Essential hypertension (first-line), mild heart failure edema, nephrogenic diabetes insipidus, calcium nephrolithiasis (hypercalciuria prevention).

Side Effects: Hypokalemia, metabolic alkalosis, hyponatremia, hypercalcemia, hyperuricemia, hyperglycemia, hyperlipidemia.

Now analyse the format or way of answer writing in previous response, now similarly answers the given questions below 👇- DRUGS AFFECTING THE MAJOR ORGANS AND SYSTEMS.1. Antitussives and expectorants: classification, mechanisms and features of action, indications, side effects.2. Bronchodilators: classification, mechanisms of action, treatment of bronchial asthma and other broncho-obstructive syndrome, side effects.3. Cardiac glycosides: mechanisms of action on the heart rate, the conductive system of the heart, hemodynamics and renal function. Indications.4. Glycoside intoxication (Digitalis Toxicity): stages, pathogenesis, symptoms, management.5. Antiarrhythmic agents I: mechanisms of action, indications, side effects.6. Calcium channel blockers: classification, mechanisms of action, indications, side effects.7. Nitrates: mechanisms and features of action, use, side effects. 8. Lipid-lowering agents: principles of action, classification. Mechanisms of action, indications, side effects of statins.9. Diuretics: mechanisms of action, classification.10.The carbonic anhydrase inhibitors and osmotic diuretics: mechanisms and features of action, uses, side effects.11.Loop diuretics, thiazides and thiazide-like diuretics: mechanisms and features of action, indications, side effects.12.Potassium-sparing diuretics: mechanisms and features of action, use, side effects.13.ACE inhibitors: mechanisms of action, indications, side effects. 14.AT1-receptor blockers: mechanisms of action, indications, side effects. 15.Antiemetic agents: classification, mechanisms and principles of action, indications, side effects.16.Drugs that reduce gastric acidity: classification, mechanisms and features of action, indications, side effects.17.Laxatives: classification, mechanisms of action, use, side effects.18.Drugs affecting the uterus: classification, mechanisms and features of action, indications, side effects.19.Antiplatelet agents: classification, mechanisms and features of action, indications, side effects.20.Heparin: origin, chemical structure, mechanisms and features of action, indications, side effects. Direct inhibitors of thrombin and Xa factor.21.Low molecular weight heparins: mechanisms and features of action, indications, side effects.22.Warfarin: mechanisms and features of action, indications, side effects.23.Thrombolytic drugs: mechanisms of action, therapeutic use, adverse effects.24.Fibrinolytic agents: classification, mechanisms of action, clinical use, side effects.25.Iron drugs: metabolism of iron, classification, mechanisms of action, clinical use, side effects.26.Cyanocobalamin (Vitamin B12): oral metabolism, clinical uses, side effects27.Drugs for diabetes mellitus type 1: insulin and insulin analogues.28.Drugs for diabetes mellitus type 2: classification, mechanisms of action, adverse effects.

Start from question 1 up to question 28

All 28 questions are now answered in full, following the same structured format as the previous response - bold subheadings, consistent section headers (Classification and Mechanisms, Indications, Side Effects, etc.), bullet points for drug lists, tables where comparison is useful, and plain descriptive prose for mechanisms. Here is a quick summary of what was covered in questions 12-28:

#	Topic	Key Drug Examples
12	Potassium-sparing diuretics	Spironolactone, eplerenone, amiloride, triamterene
13	ACE inhibitors	Enalapril, lisinopril, ramipril, captopril
14	AT₁-receptor blockers	Losartan, valsartan, candesartan
15	Antiemetic agents	Ondansetron, metoclopramide, aprepitant, scopolamine
16	Drugs reducing gastric acidity	Omeprazole, ranitidine, sucralfate, misoprostol
17	Laxatives	Lactulose, bisacodyl, psyllium, PEG, docusate
18	Drugs affecting the uterus	Oxytocin, ergometrine, misoprostol, nifedipine, atosiban
19	Antiplatelet agents	Aspirin, clopidogrel, ticagrelor, GP IIb/IIIa blockers
20	Heparin + Direct Xa/IIa inhibitors	UFH, dabigatran, rivaroxaban, apixaban
21	LMWHs	Enoxaparin, dalteparin, nadroparin
22	Warfarin	Coumarin; VKORC1 inhibition; INR monitoring
23	Thrombolytics	Alteplase, tenecteplase, streptokinase
24	Fibrinolytic agents	Generations 1-3; catheter-directed thrombolysis
25	Iron drugs	Ferrous sulfate, parenteral iron; full iron metabolism
26	Cyanocobalamin (B₁₂)	Intrinsic factor pathway; hydroxocobalamin; pernicious anemia
27	Insulin and analogues (T1DM)	Glargine, lispro, aspart, degludec; basal-bolus regimen
28	T2DM drugs	Metformin, sulfonylureas, GLP-1 agonists, SGLT-2 inhibitors, glitazones, DPP-4 inhibitors

Can you remove/cut unnecessary paragraphs, word and explanation by rewriting it. Make it more exam oriented.

Here is the fully rewritten, exam-focused version of all 28 questions.

1. Antitussives and Expectorants

Classification and Mechanisms

Central Antitussives (Opioids): Codeine, dextromethorphan - suppress the cough center in the medulla oblongata.

Peripheral Antitussives: Prenoxdiazine, levodropropizine - reduce sensitivity of respiratory tract stretch receptors.

Secretomotor Expectorants: Ammonium chloride, potassium iodide - irritate gastric mucosa to reflexively increase bronchial secretions.

Mucolytics: N-acetylcysteine (breaks disulfide bonds in mucoproteins), ambroxol (stimulates surfactant production), bromhexine.

Indications

Antitussives: Dry, non-productive cough (post-viral, lung cancer).
Expectorants/Mucolytics: Productive cough with thick sputum (bronchitis, COPD, cystic fibrosis).

Side Effects

Opioid antitussives: Sedation, constipation, respiratory depression, addiction.
Expectorants/Mucolytics: GI irritation, nausea, bronchospasm (inhaled mucolytics in asthmatics).

2. Bronchodilators

Classification and Mechanisms

β₂-Adrenergic Agonists:

SABA: Salbutamol, albuterol.
LABA: Salmeterol, formoterol.
Mechanism: β₂ stimulation → ↑cAMP → smooth muscle relaxation.

Anticholinergics:

SAMA: Ipratropium bromide.
LAMA: Tiotropium bromide.
Mechanism: Block M₃ receptors → inhibit vagal bronchoconstriction and mucus secretion.

Methylxanthines: Theophylline, aminophylline - inhibit PDE (↑cAMP) and block adenosine receptors.

Treatment of Asthma and Broncho-Obstructive Syndromes

Acute asthma: SABA (salbutamol) first-line rescue + SAMA (ipratropium).
Chronic asthma maintenance: LABA (salmeterol/formoterol) always paired with ICS.
COPD: LAMA + LABA as foundational maintenance therapy.

Side Effects

β₂-Agonists: Tremors, tachycardia, palpitations, hypokalemia.
Anticholinergics: Dry mouth, urinary retention, blurred vision, constipation.
Methylxanthines: Narrow therapeutic window - insomnia, arrhythmias, seizures, vomiting.

3. Cardiac Glycosides

Mechanisms of Action

Inhibition of Na⁺/K⁺-ATPase: Digoxin inhibits the pump → ↑intracellular Na⁺ → slows Na⁺/Ca²⁺ exchanger → ↑intracellular Ca²⁺ → enhanced contractility (positive inotropy).

Heart Rate and Conduction: Increases vagal tone → slows SA node (negative chronotropy) → prolongs AV node conduction (negative dromotropy).

Hemodynamics: ↑cardiac output → ↓LVEDP, ↓systemic vascular resistance.

Renal Function: ↑cardiac output → ↑renal perfusion → promotes diuresis → ↓RAAS activation.

Indications

Chronic HFrEF symptomatic despite optimal therapy.
Ventricular rate control in atrial fibrillation/flutter.

4. Glycoside Intoxication (Digitalis Toxicity)

Narrow therapeutic index: 0.5-2.0 ng/mL.

Pathogenesis

Excessive intracellular Ca²⁺ overload + severe Na⁺/K⁺-ATPase inhibition. Hypokalemia worsens toxicity (K⁺ competes with digoxin at pump binding site). Hypomagnesemia and hypercalcemia also increase sensitivity.

Stages and Symptoms

GI (Early): Anorexia, nausea, vomiting, abdominal pain.
Neurological/Visual: Fatigue, confusion, delirium, xanthopsia (yellow-green halos).
Cardiac (Late/Severe): ↑automaticity + ↓AV conduction → PVCs, bidirectional ventricular tachycardia, high-degree AV blocks.

Management

Stop digoxin and potassium-wasting diuretics.
Correct hypokalemia (unless high-degree AV block present).
Antiarrhythmics: Phenytoin or lidocaine (avoid Class IA agents and CCBs).
Antidote: Digoxin-specific antibody fragments (DigiFab) - for life-threatening arrhythmias, severe hyperkalemia, or massive overdose.

5. Antiarrhythmic Agents - Class I

Block voltage-gated Na⁺ channels during Phase 0 of the action potential.

Classification and Mechanisms

Class	Block Strength	Effect on APD/QT	Drugs
IA	Moderate	Prolongs (blocks Na⁺ + K⁺)	Quinidine, procainamide, disopyramide
IB	Weak	Shortens (binds inactivated channels)	Lidocaine, mexiletine
IC	Strong	No change (markedly slows Phase 0)	Flecainide, propafenone

Indications

Class IA: AF rhythm control, ventricular tachycardia.
Class IB: Acute ventricular arrhythmias (post-MI, digitalis-induced).
Class IC: SVT, AF without structural heart disease.

Side Effects

Class IA: Torsades de pointes (↑QT), drug-induced lupus (procainamide), cinchonism (quinidine).
Class IB: CNS toxicity - confusion, paresthesias, seizures, slurred speech.
Class IC: Highly proarrhythmic post-MI (CAST trial); metallic taste (propafenone).

6. Calcium Channel Blockers (CCBs)

Inhibit L-type Ca²⁺ channel influx in vascular smooth muscle and cardiac cells.

Classification and Mechanisms

Dihydropyridines (Vascular-selective): Amlodipine, nifedipine, felodipine.

Block vascular smooth muscle L-type channels → peripheral vasodilation; minimal cardiac effect.

Non-Dihydropyridines (Cardio-selective):

Verapamil (phenylalkylamine), diltiazem (benzothiazepine).
Block L-type channels in myocardium, SA node, AV node → negative inotropy, chronotropy, dromotropy.

Indications

Dihydropyridines: Hypertension, angina, Raynaud's phenomenon.
Non-Dihydropyridines: Rate control in AF/flutter, SVT prophylaxis, angina.

Side Effects

Dihydropyridines: Peripheral edema, reflex tachycardia, flushing, headache.
Non-Dihydropyridines: Bradycardia, AV block, constipation (verapamil), worsens HFrEF.

7. Nitrates

Prodrugs metabolized to release Nitric Oxide (NO).

Mechanisms and Features of Action

NO → stimulates soluble guanylyl cyclase → ↑cGMP → activates protein kinase G → dephosphorylation of myosin light chains → smooth muscle relaxation.

Therapeutic doses: Predominantly venous dilation → ↑venous capacitance → ↓preload → ↓myocardial O₂ demand.
High doses: Also arterial dilation → ↓afterload.
Nitrate tolerance: Continuous use depletes sulfhydryl groups. Prevent with a 10-12 hour nitrate-free interval daily.

Use

Acute and prophylactic angina.
Acute decompensated heart failure (↓preload).
Hypertensive emergencies (IV nitroglycerin).

Side Effects

Throbbing headache (meningeal artery dilation).
Reflex tachycardia, orthostatic hypotension, flushing.
Absolute contraindication: PDE-5 inhibitors (sildenafil) → life-threatening hypotension.

8. Lipid-Lowering Agents

Classification and Principles of Action

Class	Drugs	Primary Mechanism
Statins	Atorvastatin, rosuvastatin	Inhibit HMG-CoA reductase
Cholesterol absorption inhibitors	Ezetimibe	Block NPC1L1 transporter
PCSK9 inhibitors	Alirocumab, evolocumab	Prevent LDL receptor degradation
Fibrates	Fenofibrate, gemfibrozil	Activate PPARα → ↑lipoprotein lipase (↓TG)
Bile acid sequestrants	Cholestyramine, colesevelam	Bind bile acids in gut → ↑LDL receptor synthesis

Statins: Mechanism, Indications, Side Effects

Mechanism: Competitively inhibit HMG-CoA reductase → block HMG-CoA → mevalonate conversion (rate-limiting step) → ↓intracellular cholesterol → liver upregulates LDL receptors → ↓circulating LDL.

Indications: Hypercholesterolemia; primary and secondary prevention of MI and stroke.

Side Effects: Myalgia, myopathy, rare rhabdomyolysis (↑risk with fibrates or CYP3A4 inhibitors), elevated liver transaminases, slight ↑blood glucose. Contraindicated in pregnancy.

9. Diuretics: Classification and General Mechanisms

Diuretics increase urine output by inhibiting sodium and water reabsorption at specific nephron sites, reducing blood volume and pressure.

Classification by Nephron Site

Site	Drug Class
Proximal convoluted tubule (PCT)	Carbonic anhydrase inhibitors, osmotic diuretics
Thick ascending limb (Loop of Henle)	Loop diuretics
Distal convoluted tubule (DCT)	Thiazide and thiazide-like diuretics
Cortical collecting tubule	Potassium-sparing diuretics

10. Carbonic Anhydrase Inhibitors and Osmotic Diuretics

Carbonic Anhydrase Inhibitors (e.g., Acetazolamide)

Mechanism: Inhibits carbonic anhydrase in PCT → blocks H₂CO₃ → CO₂ + H₂O conversion → prevents NaHCO₃ reabsorption → alkaline diuresis + metabolic acidosis.

Uses: Glaucoma (↓aqueous humor), acute mountain sickness, urinary alkalinization.

Side Effects: Hyperchloremic metabolic acidosis, hypokalemia, calcium phosphate kidney stones, sulfonamide hypersensitivity.

Osmotic Diuretics (e.g., Mannitol)

Mechanism: Non-absorbable solute freely filtered at glomerulus → creates osmotic gradient in tubule → holds water in lumen. Initially extracts intracellular water → expands extracellular volume.

Uses: ↓Intracranial pressure (cerebral edema), ↓intraocular pressure.

Side Effects: Transient ECF expansion (can precipitate pulmonary edema/heart failure), dehydration, hypernatremia.

11. Loop Diuretics, Thiazides, and Thiazide-Like Diuretics

Loop Diuretics (e.g., Furosemide, Bumetanide, Torsemide)

Mechanism: Reversibly inhibit NKCC2 cotransporter in thick ascending limb → block 25% of filtered Na⁺ reabsorption → also disrupt lumen-positive potential → ↓Ca²⁺ and Mg²⁺ reabsorption.

Features: High-ceiling diuretics; effective even at low GFR.

Indications: Acute pulmonary edema, heart failure, hepatic cirrhosis, renal failure edema, severe hypercalcemia.

Side Effects: Hypokalemia, metabolic alkalosis, hypomagnesemia, hypocalcemia, hyperuricemia (gout), ototoxicity, sulfonamide allergy.

Thiazide and Thiazide-Like Diuretics (e.g., Hydrochlorothiazide, Chlorthalidone, Indapamide)

Mechanism: Inhibit NCC cotransporter in early DCT → block 5-10% Na⁺ reabsorption → ↑distal Na⁺ delivery → ↑Ca²⁺ reabsorption via basolateral Na⁺/Ca²⁺ exchanger.

Features: Lose efficacy at GFR <30 mL/min (except indapamide and metolazone).

Indications: Essential hypertension (first-line), mild heart failure, nephrogenic diabetes insipidus, calcium nephrolithiasis.

Side Effects: Hypokalemia, metabolic alkalosis, hyponatremia, hypercalcemia, hyperuricemia, hyperglycemia, hyperlipidemia.

12. Potassium-Sparing Diuretics

Classification and Mechanisms

Aldosterone Antagonists: Spironolactone, eplerenone.

Competitively block mineralocorticoid receptors in collecting duct principal cells → prevent aldosterone-driven ENaC and Na⁺/K⁺-ATPase upregulation → ↓Na⁺ reabsorption, ↓K⁺ secretion.
Spironolactone has anti-androgenic effects (steroid receptor cross-reactivity); eplerenone is more selective.

ENaC Blockers: Amiloride, triamterene.

Directly block epithelial sodium channels (ENaC) in collecting duct, independent of aldosterone → ↓electrochemical gradient driving K⁺ secretion.

Use

Combined with loop/thiazide diuretics to prevent hypokalemia.
Spironolactone: HFrEF (reduces mortality), primary hyperaldosteronism, liver cirrhosis with ascites.
Amiloride: Adjunct in hypertension, lithium-induced nephrogenic DI.

Side Effects

All: Hyperkalemia (major risk - dangerous with renal impairment or ACE inhibitors/ARBs).
Spironolactone: Gynecomastia, impotence, menstrual irregularities (anti-androgenic).
Triamterene: Kidney stones, megaloblastic anemia (folate antagonism).

13. ACE Inhibitors

Mechanism of Action

Inhibit angiotensin-converting enzyme (ACE):

↓Angiotensin II → vasodilation (↓afterload and preload) → ↓blood pressure.
↓Aldosterone → ↓Na⁺/water retention.
Bradykinin accumulates (ACE also degrades bradykinin) → additional vasodilation; causes dry cough and angioedema.
Dilate efferent arteriole → ↓intraglomerular pressure → renoprotection in diabetic/hypertensive nephropathy.

Drugs: Enalapril, lisinopril, ramipril, captopril.

Indications

Hypertension (first-line, especially with DM or CKD).
HFrEF (reduces mortality).
Post-MI (prevents ventricular remodeling).
Diabetic and proteinuric nephropathy.

Side Effects

Dry cough (bradykinin - most common reason for switching to ARB).
Angioedema (rare; bradykinin-mediated; absolute contraindication to re-use).
Hyperkalemia, first-dose hypotension.
AKI in bilateral renal artery stenosis.
Teratogenic - contraindicated in pregnancy.

14. AT₁-Receptor Blockers (ARBs)

Mechanism of Action

Selectively block AT₁ receptors → directly prevent angiotensin II effects (vasoconstriction, aldosterone release, sympathetic activation) → ↓blood pressure, ↓Na⁺ retention.

Key difference from ACEi: Do not inhibit ACE → no bradykinin accumulation → no dry cough. Angiotensin II may act on AT₂ receptors (vasodilation, anti-proliferative).

Drugs: Losartan, valsartan, candesartan, irbesartan.

Indications

Hypertension (preferred when ACEi cough occurs).
HFrEF, post-MI.
Diabetic nephropathy (T2DM - specific evidence for losartan, irbesartan).
Stroke prevention in hypertension with LVH (losartan).

Side Effects

Hyperkalemia, hypotension, AKI (same as ACEi).
No cough (main advantage over ACEi).
Angioedema (extremely rare).
Teratogenic - contraindicated in pregnancy.

15. Antiemetic Agents

Classification and Mechanisms

D₂ Receptor Antagonists: Metoclopramide, domperidone, prochlorperazine.

Block D₂ receptors in CTZ (area postrema). Metoclopramide also enhances gastric motility (prokinetic). Domperidone does not cross BBB → fewer extrapyramidal effects.

5-HT₃ Antagonists: Ondansetron, granisetron, tropisetron.

Block 5-HT₃ receptors on vagal afferents and in CTZ → highly effective for chemotherapy-induced nausea (CINV).

NK₁ Receptor Antagonists: Aprepitant, fosaprepitant.

Block substance P at NK₁ receptors → effective for delayed CINV (combined with 5-HT₃ antagonist + dexamethasone).

H₁ Antihistamines: Dimenhydrinate, meclizine, promethazine.

Block H₁ receptors in vestibular nuclei → motion sickness.

Anticholinergics: Scopolamine (transdermal) - block muscarinic receptors in vestibular system → motion sickness.

Corticosteroids: Dexamethasone - adjunct in CINV regimens.

Indications

Ondansetron: CINV, PONV.
Aprepitant: Delayed CINV.
Metoclopramide: Gastroparesis, GERD, postoperative nausea.
Dimenhydrinate/Scopolamine: Motion sickness, Meniere's disease.
Domperidone: Nausea in Parkinson's disease.

Side Effects

D₂ Antagonists: Extrapyramidal effects (dystonia, akathisia, tardive dyskinesia), hyperprolactinemia, sedation.
5-HT₃ Antagonists: Headache, constipation, QT prolongation.
NK₁ Antagonists: Fatigue, hiccups, CYP3A4 inhibition (drug interactions).
H₁ Antihistamines/Scopolamine: Sedation, dry mouth, blurred vision, urinary retention.

16. Drugs That Reduce Gastric Acidity

Classification and Mechanisms

Proton Pump Inhibitors (PPIs): Omeprazole, pantoprazole, lansoprazole, esomeprazole.

Prodrugs activated in acidic parietal cell canaliculi → irreversibly inhibit H⁺/K⁺-ATPase (proton pump) → most potent acid suppression. Take 30 minutes before meals.

H₂ Receptor Antagonists: Ranitidine, famotidine, cimetidine.

Competitively block H₂ receptors on parietal cells → ↓histamine-stimulated acid secretion. Tolerance develops with continuous use.

Antacids: Aluminum hydroxide, magnesium hydroxide, calcium carbonate.

Chemically neutralize secreted HCl. Rapid but short-lived relief. Al³⁺ → constipation; Mg²⁺ → diarrhea.

Mucosal Protectants:

Sucralfate: Polymerizes in acid → adheres to ulcer craters → physical protection.
Misoprostol (PGE₁ analogue): ↑mucus/bicarbonate secretion, ↓acid secretion → prevents NSAID-induced gastropathy.
Bismuth subcitrate: Coats ulcer craters, anti-H. pylori activity.

Indications

PPIs: GERD, PUD, H. pylori eradication, Zollinger-Ellison syndrome, NSAID ulcer prevention.
H₂RAs: Mild GERD, PUD, stress ulcer prophylaxis.
Antacids: Symptomatic heartburn relief.
Misoprostol: NSAID-induced ulcer prevention (high-risk patients).

Side Effects

PPIs (long-term): Hypomagnesemia, C. difficile infection risk, osteoporosis/fractures, B₁₂ malabsorption, rebound acid hypersecretion on discontinuation.
H₂RAs: Cimetidine - gynecomastia, impotence, CYP450 inhibition (multiple drug interactions).
Antacids: Constipation (Al), diarrhea (Mg), milk-alkali syndrome (Ca), impaired absorption of other drugs.
Misoprostol: Diarrhea, abdominal cramps. Contraindicated in pregnancy (uterotonic).

17. Laxatives

Classification and Mechanisms

Bulk-Forming: Psyllium, methylcellulose, bran.

Absorb water → swell → ↑stool bulk → stimulate peristalsis via stretch receptors. Safest long-term; must take with adequate water.

Osmotic: Lactulose, PEG (macrogol), magnesium hydroxide, sorbitol.

Non-absorbable solutes → retain water in lumen → ↑luminal volume → stimulate motility. Lactulose also acidifies colon → traps NH₄⁺ (used in hepatic encephalopathy).

Stimulant (Contact): Bisacodyl, senna, sodium picosulfate, castor oil.

Stimulate myenteric plexus → ↑peristalsis; inhibit colonic water/electrolyte absorption.

Stool Softeners: Docusate sodium.

Anionic surfactant → reduces surface tension → allows water/lipid penetration of stool.

Lubricants: Liquid paraffin (mineral oil).

Coats feces → prevents water reabsorption → lubricates passage.

Use

Bulk-forming: Chronic constipation, IBS-C, pregnancy.
Lactulose: Constipation, hepatic encephalopathy.
PEG: Chronic constipation, bowel prep for colonoscopy.
Stimulant: Short-term acute constipation, procedure bowel prep.
Docusate: Post-surgical/post-MI (avoid straining).

Side Effects

Bulk-forming: Bloating, flatulence, obstruction if taken without water.
Lactulose: Flatulence, cramping, diarrhea.
Stimulant (chronic): Hypokalemia, melanosis coli (anthraquinones), laxative dependence.
Liquid paraffin: Lipid pneumonia (aspiration), fat-soluble vitamin malabsorption.

18. Drugs Affecting the Uterus

Classification and Mechanisms

Uterotonics:

Oxytocin/Carbetocin: Bind Gq-coupled oxytocin receptors → ↑IP₃ → ↑intracellular Ca²⁺ → rhythmic myometrial contractions. Short half-life (~5 min); carbetocin lasts ~1 hour.

Ergot Alkaloids (Ergometrine, Methylergometrine): Partial agonists at 5-HT₂, dopamine, and α-adrenergic receptors → sustained tetanic contractions + vasoconstriction. Not for labor induction.

Prostaglandins (Dinoprostone-PGE₂, Carboprost-PGF₂α, Misoprostol-PGE₁): Bind EP/FP receptors → ↑Ca²⁺ → contractions. PGE₂ also causes cervical ripening.

Tocolytics (Uterine Relaxants):

β₂-Agonists (Ritodrine, Terbutaline): Stimulate β₂ receptors → ↑cAMP → ↑PKA → phosphorylates and inactivates MLCK → relaxation.

Nifedipine (CCB): Blocks L-type Ca²⁺ channels in myometrium → ↓contractions. Preferred tocolytic.

Atosiban: Competitive oxytocin receptor antagonist → directly inhibits contractions.

Magnesium Sulfate: Competes with Ca²⁺ at myometrial membrane + fetal neuroprotection.

Indications

Oxytocin: Labor induction/augmentation; postpartum hemorrhage (PPH) first-line.
Ergometrine: PPH treatment (second-line).
Misoprostol/Dinoprostone: Cervical ripening, labor induction, medical abortion, PPH.
Tocolytics (nifedipine, atosiban): Preterm labor - delay delivery to allow fetal lung maturation with corticosteroids.

Side Effects

Oxytocin: Water retention/hyponatremia, hypotension, uterine hyperstimulation, fetal distress, uterine rupture.
Ergometrine: Hypertension (contraindicated in pre-eclampsia), coronary vasospasm (contraindicated in IHD), nausea/vomiting.
Carboprost: Bronchospasm (contraindicated in asthma), diarrhea, fever.
β₂-Agonist tocolytics: Tachycardia, hyperglycemia, hypokalemia, pulmonary edema (IV use).
MgSO₄: Flushing, respiratory depression, cardiac arrest at toxic levels. Antidote: calcium gluconate.

19. Antiplatelet Agents

Classification and Mechanisms

COX Inhibitors: Aspirin.

Irreversibly acetylates COX-1 → blocks TXA₂ synthesis (platelet activator/vasoconstrictor) for platelet lifetime (7-10 days). Low dose (75-150 mg) preferentially inhibits platelet TXA₂ while sparing endothelial PGI₂.

P2Y₁₂ ADP Receptor Antagonists:

Thienopyridines (prodrugs): Clopidogrel, prasugrel, ticlopidine → irreversibly block P2Y₁₂ after CYP activation.
Direct-acting: Ticagrelor (reversible, oral), cangrelor (reversible, IV) → direct P2Y₁₂ block, no CYP dependence.

GP IIb/IIIa Receptor Antagonists: Abciximab, eptifibatide, tirofiban (IV only).

Block the final common pathway of platelet aggregation (fibrinogen cannot cross-link platelets).

PDE Inhibitors: Dipyridamole, cilostazol.

↑cAMP → suppress platelet activation. Dipyridamole also inhibits adenosine reuptake.

Indications

Aspirin: ACS, post-MI, ischemic stroke/TIA prevention, post-PCI.
Clopidogrel/Ticagrelor/Prasugrel: ACS (DAPT with aspirin), post-coronary stenting, PAD.
GP IIb/IIIa Antagonists: High-risk PCI.
Dipyridamole + Aspirin: Secondary stroke/TIA prevention.
Cilostazol: Intermittent claudication.

Side Effects

Aspirin: GI bleeding, peptic ulceration, hypersensitivity (aspirin-exacerbated respiratory disease), Reye's syndrome (children).
Clopidogrel: Bleeding; variable response (CYP2C19 polymorphism). TTP with ticlopidine.
Ticagrelor: Bleeding, dyspnea (adenosine-mediated), bradycardia.
GP IIb/IIIa Antagonists: Bleeding, thrombocytopenia.
Cilostazol: Headache, palpitations. Contraindicated in heart failure.

20. Heparin: Origin, Structure, Mechanisms, Indications, Side Effects. Direct Thrombin and Xa Inhibitors

Heparin

Origin/Structure: Naturally occurring glycosaminoglycan from porcine intestinal mucosa or bovine lung. Sulfated polysaccharide (MW 3,000-30,000 Da, mean ~15,000 Da) with a key pentasaccharide sequence that binds antithrombin III (AT-III).

Mechanism: Binds AT-III → conformational change → AT-III inhibitory activity ↑1,000-10,000x → irreversibly inhibits thrombin (IIa), Factor Xa, IXa, XIa, XIIa. UFH inhibits IIa and Xa equally.

Features:

IV infusion or subcutaneous. Not orally bioavailable.
Cannot cross placenta → safe in pregnancy.
Monitored by aPTT (target 1.5-2.5x control).
Antidote: Protamine sulfate.

Indications: DVT/PE treatment and prevention, ACS, cardiac surgery, hemodialysis, perioperative bridging.

Side Effects:

Bleeding (primary risk).
HIT Type II (immune-mediated: IgG antibodies vs. heparin-PF4 complexes → paradoxical thrombosis + thrombocytopenia; stop heparin immediately → switch to direct thrombin inhibitor, e.g., argatroban).
Osteoporosis (long-term), elevated liver transaminases.

Direct Thrombin Inhibitors (DTIs)

Parenteral: Argatroban (hepatic clearance - use in HIT/renal failure), bivalirudin (PCI).
Oral: Dabigatran etexilate (renal clearance). Antidote: Idarucizumab.
Mechanism: Directly bind thrombin active site, AT-III-independent. Inhibit both free and clot-bound thrombin.

Direct Factor Xa Inhibitors

Oral: Rivaroxaban, apixaban, edoxaban.
Parenteral: Fondaparinux (synthetic pentasaccharide; AT-III-dependent, anti-Xa only).
Mechanism: Directly inhibit Factor Xa → block prothrombin → thrombin conversion.
Antidote: Andexanet alfa (for rivaroxaban/apixaban). No specific antidote for fondaparinux.
Indications: AF stroke prevention, DVT/PE treatment, post-orthopedic thromboprophylaxis.

21. Low Molecular Weight Heparins (LMWHs)

Derived from UFH by depolymerization → MW 1,000-10,000 Da (mean ~5,000 Da).

Mechanisms and Features

Mechanism: Act via AT-III. Shorter chains → preferential anti-Xa over anti-IIa activity (2:1 to 4:1) (too short to bridge AT-III and thrombin simultaneously).

Advantages over UFH:

Predictable pharmacokinetics; >90% subcutaneous bioavailability.
Longer half-life (4-6 h) → once/twice daily dosing.
No routine aPTT monitoring (anti-Xa levels in special populations).
Lower HIT Type II risk.
Partial reversal with protamine (neutralizes anti-IIa, not anti-Xa).

Drugs: Enoxaparin, dalteparin, nadroparin, tinzaparin.

Indications

DVT/PE prevention and treatment.
ACS (unstable angina, NSTEMI).
Anticoagulation in pregnancy (drug of choice with UFH).
Perioperative bridging anticoagulation.

Side Effects

Bleeding (less than UFH at equivalent doses).
HIT Type II (less frequent than UFH but possible).
Injection-site bruising/hematoma.
Accumulation in renal failure (renally cleared) → dose reduce or switch to UFH if CrCl <30 mL/min.

22. Warfarin

Oral anticoagulant; vitamin K antagonist (coumarin class).

Mechanisms and Features

Mechanism: Inhibits VKORC1 → blocks recycling of vitamin K epoxide → depletes active vitamin K hydroquinone → impairs γ-carboxylation of clotting factors II, VII, IX, X and anticoagulant Protein C and Protein S.

Features:

Delayed onset: 2-3 days (existing factors consumed first; Factor VII falls first → early INR rise).
Full effect: 5-7 days.
Monitored by INR (target 2.0-3.0 for most; 2.5-3.5 for mechanical valves).
99% protein-bound → extensive drug interactions.
Teratogenic - contraindicated in pregnancy (1st and 3rd trimesters).
Antidote: Vitamin K₁ (12-24 h reversal); urgent: 4-factor PCC or FFP.

Drug interactions: ↑effect: CYP2C9 inhibitors (amiodarone, fluconazole, metronidazole), aspirin, broad-spectrum antibiotics. ↓effect: CYP2C9 inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort), dietary vitamin K.

Indications

AF stroke prevention (valvular AF or DOAC-contraindicated).
DVT/PE treatment and secondary prevention.
Mechanical prosthetic heart valves (only anticoagulant approved).
Antiphospholipid syndrome.

Side Effects

Bleeding (intracranial hemorrhage most feared).
Warfarin skin necrosis (days 3-5; Protein C/S deficiency → transient hypercoagulable state).
Teratogenicity: Warfarin embryopathy (weeks 6-12); fetal hemorrhage (3rd trimester).
Purple toe syndrome, extensive drug/food interactions.

23. Thrombolytic Drugs

Mechanisms of Action

Activate plasminogen → plasmin → cleaves fibrin → clot dissolution. Also degrade fibrinogen, Factor V, Factor VIII (systemic lytic state).

Drug	Selectivity	Features
Streptokinase	Non-selective	Bacterial; forms 1:1 complex with plasminogen; antigenic; cannot re-use
Alteplase (rt-PA)	Fibrin-selective	Recombinant tPA; activates fibrin-bound plasminogen; short t½ (5 min), continuous infusion
Tenecteplase	High fibrin-selective	Single IV bolus; resistant to PAI-1
Reteplase	Moderate selective	Double bolus; longer t½ than alteplase
Urokinase	Non-selective	Human serine protease; direct plasminogen activator; catheter use

Therapeutic Use

STEMI: When PCI not available within 120 min (alteplase, tenecteplase preferred).
Massive PE with hemodynamic instability.
Acute ischemic stroke: Alteplase/tenecteplase within 4.5 hours of onset.
Massive DVT with limb-threatening ischemia (catheter-directed).

Adverse Effects

Bleeding (major complication) - intracranial hemorrhage (~0.9-1% in stroke).
Streptokinase: Allergic/anaphylactic reactions, hypotension (bradykinin), resistance on re-exposure.
Reperfusion arrhythmias (post-coronary thrombolysis - usually transient).

Absolute contraindications: Prior intracranial hemorrhage, active internal bleeding, recent intracranial surgery/trauma, intracranial neoplasm, severe uncontrolled hypertension.

24. Fibrinolytic Agents

Classification

Generation	Drugs	Selectivity
1st (non-selective)	Streptokinase, urokinase	Systemic plasminogen activation; high bleeding risk
2nd (fibrin-selective)	Alteplase (rt-PA)	Preferential fibrin-bound plasminogen activation
3rd (enhanced)	Tenecteplase, reteplase	Greater fibrin selectivity; PAI-1 resistance; bolus dosing

Mechanisms

All produce plasmin from plasminogen → cleaves fibrin → produces fibrin degradation products (FDPs) and D-dimers (clinical markers of fibrinolysis).

Clinical Use

Same as thrombolytics (STEMI, massive PE, acute ischemic stroke).
Catheter-Directed Thrombolysis (CDT): Low-dose fibrinolytic infused directly into thrombus via catheter → higher local effect, lower systemic dose → ↓bleeding risk. Used for sub-massive PE, iliofemoral DVT, peripheral arterial occlusion.

Side Effects

Same as thrombolytics. Key differentiator: streptokinase is antigenic and cannot be re-used within 6-12 months.

25. Iron Drugs

Metabolism of Iron

Reduction: Dietary Fe³⁺ → Fe²⁺ by duodenal cytochrome B (DcytB).
Intestinal absorption: Fe²⁺ enters enterocyte via DMT-1 (duodenum/upper jejunum).
Export: Fe²⁺ exported via ferroportin → oxidized to Fe³⁺ by hephaestin → binds transferrin for plasma transport.
Cellular uptake: Transferrin-Fe³⁺ → binds TfR1 receptors → endocytosis → Fe³⁺ reduced to Fe²⁺ by STEAP3 → released to cytoplasm.
Storage: Ferritin (soluble, short-term) and hemosiderin (insoluble, long-term) in liver, spleen, bone marrow.
Regulation: Hepcidin (liver) binds ferroportin → internalization/degradation → blocks iron export. Inflammation ↑hepcidin → anemia of chronic disease.
Excretion: No regulated excretion (lost via epithelial shedding, menstruation).

Classification

Oral (Fe²⁺ salts): Ferrous sulfate (first-line), ferrous gluconate, ferrous fumarate.
Parenteral: Iron sucrose, ferric carboxymaltose, iron dextran, ferumoxytol.

Mechanisms and Clinical Use

Replenish iron stores → restore Hb synthesis, myoglobin, cytochromes.
Oral iron: Take fasting with vitamin C (enhances absorption). Reticulocyte ↑in 3-5 days; Hb rises at 1-2 weeks; continue 3-6 months after normalization to replenish stores.
Parenteral iron: Used when oral not tolerated/absorbed; IBD, CKD on dialysis, heart failure, pre-operative anemia.

Side Effects

Oral: Nausea, epigastric discomfort, constipation, black stools (harmless). GI intolerance → poor compliance.

Parenteral: Anaphylaxis/hypersensitivity (especially high-MW iron dextran), hypotension, arthralgia, iron overload.

Acute overdose (children): GI toxicity → apparent recovery → metabolic acidosis, hepatotoxicity, shock. Treatment: gastric lavage + deferoxamine (chelating agent).

26. Cyanocobalamin (Vitamin B₁₂)

Oral Metabolism

Stomach: Pepsin/acid releases B₁₂ from food → B₁₂ binds R-protein (haptocorrin); parietal cells secrete Intrinsic Factor (IF).
Duodenum: Pancreatic proteases degrade R-protein → free B₁₂ binds IF → IF-B₁₂ complex formed.
Terminal ileum: IF-B₁₂ binds cubilin receptors → endocytosis → B₁₂ released → enters portal circulation bound to transcobalamin II.
Storage: Liver stores 2,000-5,000 μg (3-5 years supply).

Causes of deficiency: Pernicious anemia (autoimmune destruction of parietal cells → no IF), gastrectomy, atrophic gastritis, terminal ileum disease/resection (Crohn's), strict veganism, long-term metformin/PPI use.

Passive absorption: 1-2% absorbed by passive diffusion throughout small intestine (basis for high-dose oral therapy: 1,000-2,000 μg/day even in pernicious anemia).

Clinical Uses

Biochemical roles:

Methylcobalamin: Cofactor for methionine synthase → homocysteine → methionine. Deficiency → "folate trap" → ↓THF → impaired DNA synthesis → megaloblastic anemia.
Adenosylcobalamin: Cofactor for methylmalonyl-CoA mutase → methylmalonyl-CoA → succinyl-CoA. Deficiency → MMA accumulates → subacute combined degeneration of the spinal cord (posterior + lateral column degeneration).

Indications:

Megaloblastic (macrocytic) anemia due to B₁₂ deficiency.
Pernicious anemia (IM hydroxocobalamin or high-dose oral).
Subacute combined degeneration of spinal cord.
Prevention in at-risk groups (vegans, post-gastrectomy, elderly, long-term metformin/PPI users).

Formulations: Cyanocobalamin (synthetic, stable), hydroxocobalamin (longer-acting; also antidote for cyanide poisoning), methylcobalamin, adenosylcobalamin.

Side Effects

Generally extremely safe (water-soluble; excess excreted).

Rare: mild diarrhea, skin rash.
IM injection: local pain, reactions.
Hypokalemia (during initial treatment of severe megaloblastic anemia - rapid erythropoiesis consumes K⁺).

27. Drugs for Diabetes Mellitus Type 1: Insulin and Insulin Analogues

Mechanism of Action

Insulin binds transmembrane tyrosine kinase insulin receptor → IRS-1/PI3K/Akt cascade:

↑GLUT-4 translocation (↑glucose uptake in muscle/adipose).
↑Glycogen synthesis (liver/muscle).
↑Lipogenesis, ↓lipolysis.
↑Protein synthesis.
↓Gluconeogenesis, glycogenolysis, ketogenesis.

Classification by Duration

Type	Drugs	Onset	Peak	Duration
Rapid-Acting	Lispro, aspart, glulisine	5-15 min	30-90 min	3-5 h
Short-Acting (Regular)	Actrapid/neutral insulin	30-60 min	2-3 h	5-8 h
Intermediate	NPH (Isophane)	1-2 h	4-8 h	12-18 h
Long-Acting	Glargine, detemir	1-2 h	Peakless	20-24 h
Ultra-Long	Degludec	30-90 min	Peakless	>42 h

Rapid-acting analogues: Engineered to exist as monomers at injection site → faster absorption. Lispro: B28-B29 reversal; aspart: B28 Pro→Asp.

Long-acting analogues: Glargine: A21 mutation + 2 Arg additions → microprecipitates at physiological pH → slow release. Detemir: fatty acid acylation → albumin binding → buffered release.

Insulin Regimens in T1DM

Basal-Bolus (Gold Standard): Long-acting (glargine/detemir) once daily + rapid-acting (lispro/aspart) before each meal.
CSII (Insulin Pump): Continuous subcutaneous rapid-acting insulin; programmable basal + bolus doses.

Side Effects

Hypoglycemia (primary risk): Adrenergic symptoms (sweating, tremor, palpitations) → neuroglycopenic symptoms (confusion, seizures, coma).
Weight gain.
Lipohypertrophy at injection sites (rotate sites).
Hypokalemia (K⁺ driven into cells).
Edema at treatment initiation.

28. Drugs for Diabetes Mellitus Type 2

T2DM: Peripheral insulin resistance + progressive beta-cell dysfunction.

Classification and Mechanisms

Biguanides - Metformin (First-Line):

Activates AMPK via ↑AMP:ATP ratio (inhibits mitochondrial Complex I) → ↓hepatic gluconeogenesis (primary effect) + ↑peripheral insulin sensitivity.
No hypoglycemia; weight-neutral to mildly reducing. ↓Cardiovascular events.
Adverse effects: GI (nausea, diarrhea - take with food), lactic acidosis (rare; hold before contrast media), B₁₂ malabsorption. Contraindicated if eGFR <30.

Sulfonylureas (Glibenclamide, Gliclazide, Glimepiride, Glipizide):

Close K_ATP channels on beta-cells → depolarization → ↑Ca²⁺ → insulin secretion (glucose-independent).
Adverse effects: Hypoglycemia (major, especially glibenclamide in elderly/renal impairment), weight gain.

Meglitinides/Glinides (Repaglinide, Nateglinide):

Same K_ATP mechanism; rapid onset and short duration → prandial insulin secretion (take with meals only).
Adverse effects: Hypoglycemia (less than sulfonylureas), weight gain.

Thiazolidinediones/Glitazones (Pioglitazone, Rosiglitazone):

Activate PPARγ → ↑GLUT-4 expression, ↑adiponectin → ↑peripheral insulin sensitivity. Slow onset (weeks).
Adverse effects: Fluid retention/edema (contraindicated in heart failure), weight gain, bone fractures (women), rosiglitazone → ↑MI risk, pioglitazone → possible bladder cancer.

DPP-4 Inhibitors/Gliptins (Sitagliptin, Saxagliptin, Linagliptin, Vildagliptin):

Inhibit DPP-4 → prevent incretin (GLP-1, GIP) degradation → ↑GLP-1/GIP → glucose-dependent insulin secretion + ↓glucagon. Minimal hypoglycemia risk; weight-neutral.
Adverse effects: Nasopharyngitis, UTIs. Rare: acute pancreatitis. Saxagliptin/alogliptin → ↑heart failure hospitalization.

GLP-1 Receptor Agonists (Liraglutide, Semaglutide, Dulaglutide, Exenatide):

Bind GLP-1 receptors → glucose-dependent insulin secretion + ↓glucagon + ↓gastric emptying + central appetite suppression → significant weight loss (5-10%). ↓MACE in established CVD (LEADER, SUSTAIN-6 trials). SC injection (except oral semaglutide).
Adverse effects: Nausea, vomiting, diarrhea (most common; dose-dependent). Rare: pancreatitis. Contraindicated in MEN2/medullary thyroid carcinoma (thyroid C-cell risk in rodents). Gallstones.

SGLT-2 Inhibitors/Gliflozins (Empagliflozin, Dapagliflozin, Canagliflozin):

Inhibit SGLT-2 in PCT → block ~90% of filtered glucose reabsorption → glucosuria (60-100g/day) → ↓blood glucose (insulin-independent). Also cause natriuresis → ↓BP, ↓preload. Profound ↓heart failure hospitalization + renoprotection (EMPA-REG, CANVAS, DECLARE trials). Weight loss.
Adverse effects: Genital mycotic infections, UTIs (glucosuria). Euglycemic DKA (rare but serious). Fournier's gangrene (rare). Polyuria, volume depletion. Canagliflozin: ↑lower limb amputations and bone fractures (FDA black box warning).

Alpha-Glucosidase Inhibitors (Acarbose, Miglitol):

Inhibit intestinal brush-border alpha-glucosidases → delay carbohydrate digestion/absorption → ↓postprandial glucose. No systemic absorption; no hypoglycemia alone; modest efficacy.
Adverse effects: Flatulence, bloating, diarrhea (fermentation of undigested carbohydrates) - major limitation.

All 28 questions are now written in a concise, exam-oriented format - essential mechanisms, key drugs, core indications, and must-know side effects only. No filler explanations.

Analyse all 1 to 28 questions, write the chapter name of pharmacology the belongs to.

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

This is a shared conversation. Sign in to Orris to start your own chat.